Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer

Lung Cancer

Volumn 83, Issue 1, 2014, Pages 37-43

  Yamaguchi, Norihiro ^a   Lucena Araujo, Antonio R ^a   Nakayama, Sohei ^a   de Figueiredo Pontes, Lorena L ^a   Gonzalez, David A ^a   Yasuda, Hiroyuki ^a   Kobayashi, Susumu ^a   Costa, Daniel B ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Anaplastic lymphoma kinase; Crizotinib; Epidermal growth factor receptor; Kinase inhibitor; Non small cell lung cancer; Tyrosine kinase

Indexed keywords

AFATINIB; CRIZOTINIB; ERLOTINIB; PROTEIN TYROSINE KINASE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CLONE; CONTROLLED STUDY; CULTURE MEDIUM; DRUG MECHANISM; GENE AMPLIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; LUNG CANCER; PRIORITY JOURNAL;

ANAPLASTIC LYMPHOMA KINASE; CRIZOTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; KINASE INHIBITOR; NON-SMALL-CELL LUNG CANCER; TYROSINE KINASE;

CARCINOMA, NON-SMALL-CELL LUNG; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE AMPLIFICATION; GENE REARRANGEMENT; HUMANS; LUNG NEOPLASMS; MICROARRAY ANALYSIS; MUTATION; ONCOGENE PROTEINS, FUSION; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRAZOLES; PYRIDINES; QUINAZOLINES; RECEPTOR PROTEIN-TYROSINE KINASES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84891738696     PISSN: 01695002     EISSN: 18728332     Source Type: Journal    
DOI: 10.1016/j.lungcan.2013.09.019     Document Type: Article

References (26)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013, 63(1):11-30.
3. Pao W., Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011, 12(2):175-180.
4. Soda M., Choi Y.L., Enomoto M., Takada S., Yamashita Y., Ishikawa S., et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007, 448(7153):561-566.
5. Yasuda H., Figueiredo-Pontes L.L., Kobayashi S., Costa D.B. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer. J Thorac Oncol 2012, 7(7):1086-1090.
6. Kwak E.L., Bang Y.J., Camidge D.R., Shaw A.T., Solomon B., Maki R.G., et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010, 363(18):1693-1703.
7. Ou S.H., Bartlett C.H., Mino-Kenudson M., Cui J., Iafrate A.J. Crizotinib for the treatment of ALK-rearranged non-small cell lung cancer: a success story to usher in the second decade of molecular targeted therapy in oncology. Oncologist 2012, 17(11):1351-1375.
8. Camidge D.R., Doebele R.C. Treating ALK-positive lung cancer - early successes and future challenges. Nat Rev Clin Oncol 2012, 9(5):268-277.
9. Camidge D.R., Bang Y.J., Kwak E.L., Iafrate A.J., Varella-Garcia M., Fox S.B., et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012, 13(10):1011-1019.
10. Shaw A.T., Engelman J.A. ALK in lung cancer: past, present, and future. J Clin Oncol 2013, 31(8):1105-1111.
11. Costa D.B., Kobayashi S., Pandya S.S., Yeo W.L., Shen Z., Tan W., et al. CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 2011, 29(15):e443-e445.
12. Nguyen K.S., Kobayashi S., Costa D.B. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer 2009, 10(4):281-289.
13. Ohashi K., Maruvka Y.E., Michor F., Pao W. Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 2013, 31(8):1070-1080.
14. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 2005, 352(8):786-792.
15. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005, 2(3):e73.
16. Choi Y.L., Soda M., Yamashita Y., Ueno T., Takashima J., Nakajima T., et al. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors. N Engl J Med 2010, 363(18):1734-1739.
17. Katayama R., Shaw A.T., Khan T.M., Mino-Kenudson M., Solomon B.J., Halmos B., et al. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung cancers. Sci Transl Med 2012, 4(120):120ra17.
18. Lovly C.M., Pao W. Escaping ALK inhibition: mechanisms of and strategies to overcome resistance. Sci Transl Med 2012, 4(120):120ps2.
19. Sasaki T., Koivunen J., Ogino A., Yanagita M., Nikiforow S., Zheng W., et al. A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors. Cancer Res 2011, 71(18):6051-6060.
20. Tanizaki J., Okamoto I., Okabe T., Sakai K., Tanaka K., Hayashi H., et al. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer. Clin Cancer Res 2012, 18(22):6219-6226.
21. Doebele R.C., Pilling A.B., Aisner D.L., Kutateladze T.G., Le A.T., Weickhardt A.J., et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res 2012, 18(5):1472-1482.
22. Costa D.B., Kobayashi S. Acquired resistance to the ALK inhibitor crizotinib in the absence of an ALK mutation. J Thorac Oncol 2012, 7(3):623-625.
23. Weir B.A., Woo M.S., Getz G., Perner S., Ding L., Beroukhim R., et al. Characterizing the cancer genome in lung adenocarcinoma. Nature 2007, 450(7171):893-898.
24. Basseres D.S., D'Alo F., Yeap B.Y., Lowenberg E.C., Gonzalez D.A., Yasuda H., et al. Frequent downregulation of the transcription factor Foxa2 in lung cancer through epigenetic silencing. Lung Cancer 2012, 77(1):31-37.
25. Tan W., Wilner K.D., Bang Y., Kwak E.L., Maki R.G., Camidge D.R., et al. Pharmacokinetics (PK) of PF-02341066, a dual ALK/MET inhibitor after multiple oral doses to advanced cancer patients. J Clin Oncol 2010, 28(7s). [suppl; abstract 2596].
26. Kim S., Kim T.M., Kim D.W., Go H., Keam B., Lee S.H., et al. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer. J Thorac Oncol 2013, 8(4):415-422.